ReviewApplied health economics and health policy2026
When Does Health Technology Assessment Need Deliberation? Evidence, Algorithms and the Limits of Consultation.
Review in Applied health economics and health policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health technology assessment (HTA) increasingly depends on formal methods such as cost-effectiveness analysis, QALYs, thresholds, structured evidence reviews and decision criteria. These tools are indispensable, but they do not remove the need for judgement. Decisions about health technologies often involve heterogeneous evidence, uncertainty, contested values, institutional constraints, professional responsibilities and consequences for both identifiable patients and anonymous others whose care may be displaced. In this article, we ask when deliberation is likely to be needed in HTA, and what distinguishes it from algorithmic reasoning, consultation and commenting. We argue that deliberation should not be defended simply because it is democratic, inclusive or procedurally attractive. Its value is conditional. Deliberation becomes useful where evidence does not combine itself, where values shape what counts as relevant evidence, and where recommendations must be justified in ways that can withstand disagreement. We distinguish context-free scientific evidence, context-sensitive scientific evidence, and colloquial evidence, and show why their interpretation cannot be reduced to evidence accumulation or modelled calculation. We then identify the circumstances in which deliberation is most likely to add value: (1) when evidence is heterogeneous, incomplete, contested or context dependent, (2) when values, outcomes, equity or fairness are disputed, (3) when implementation is uncertain, and (4) when professional ownership, public credibility or political trust matter. We argue that HTA does not need deliberation everywhere, but where judgement must be exercised, exposed and justified.
Identifiers
42722977What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.